Source: Annual Congress 2003 - Intervention strategies in chronic respiratory failure
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Ramponi, F. Casanova, R. Guarnieri, R. Cogo (Cassano D'Adda, Italy). Efficacy of a new standardised approach in reducing severe exacerbations in end stage COPD. Eur Respir J 2003; 22: Suppl. 45, 3615

Member's Comments

No comment yet.

Related content which might interest you: Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Importance of the initial behaviour of patients in avoiding late recovery from COPD exacerbations Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 Agreement of severity stages and exacerbations building the new COPD risk groups Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013 Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study Source: International Congress 2017 – Management of COPD Year: 2017 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability Source: International Congress 2014 – Markers Year: 2014 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015 Assessing the burden of repeated exacerbations among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 The therapeutic strategies in severe and very severe COPD: a cost-efficacy analysis in Italy Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 Impact of stable state symptoms on the future burden of COPD exacerbations Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Decaf score for predicting treatment escalation in exacerbations of COPD Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Tiotropium reduces the risk of COPD exacerbation irrespective of its characterization by the treatment intervention Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 COPD exacerbations: impact and prevention Source: Breathe 2013; 9: 434-440 Year: 2013